Navidea Biopharmaceuticals Announces Positive Results of First Interim Analysis of Ongoing Phase 2B Study in Rheumatoid Arthritis
Navidea Biopharmaceuticals, Inc. (NAVB)
NASDAQ:AMEX Investor Relations:
ir.navidea.com
Company Research
Source: Business Wire
Data Demonstrated Quantitative Repeatability and Stability of SignalCompany Continues to Enroll Subjects as Planned to Complete the Phase 2B and Prepare for the Upcoming Phase 3 Trial DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce positive results from the Company’s first interim analysis of its ongoing NAV3-31 Phase 2B study. Analysis demonstrates that these interim data support Navidea’s hypotheses that Tc 99m Tilmanocept imaging can provide robust, quantitative imaging in healthy controls and in patients with active rheumatoid arthritis (“RA”) and that this imaging is stable, reproducible, and can define joints with and without RA-involved inflammation.Navidea’s NAV3-31 Phase 2B trial titled “Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc 99m Tilmanocept P
Show less
Read more
Impact Snapshot
Event Time:
NAVB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NAVB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NAVB alerts
High impacting Navidea Biopharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
NAVB
News
- Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat